← All trials
NCT05267613
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2022
- Primary completion
- Aug 14, 2026
- Completion date
- Nov 6, 2026
- First posted
- Mar 4, 2022
- Last posted
- Dec 9, 2022
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- Center for Information and Study on Clinical Research Participation (CISCRP)Collaborator
- IQVIACollaborator
- LabCorpCollaborator
- Medidata SolutionsCollaborator
- Thermo Fisher ScientificCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.